CN116635027A - C-利钠肽的延长释放水凝胶偶联物 - Google Patents

C-利钠肽的延长释放水凝胶偶联物 Download PDF

Info

Publication number
CN116635027A
CN116635027A CN202180079063.9A CN202180079063A CN116635027A CN 116635027 A CN116635027 A CN 116635027A CN 202180079063 A CN202180079063 A CN 202180079063A CN 116635027 A CN116635027 A CN 116635027A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
independently
attached
hydrogel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180079063.9A
Other languages
English (en)
Chinese (zh)
Inventor
E·L·施奈德
B·R·赫恩
D·V·圣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolynx LLC
Original Assignee
Prolynx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx LLC filed Critical Prolynx LLC
Publication of CN116635027A publication Critical patent/CN116635027A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202180079063.9A 2020-11-25 2021-11-24 C-利钠肽的延长释放水凝胶偶联物 Pending CN116635027A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118568P 2020-11-25 2020-11-25
US63/118,568 2020-11-25
PCT/US2021/060763 WO2022115563A1 (en) 2020-11-25 2021-11-24 Extended release hydrogel conjugates of c-natriuretic peptides

Publications (1)

Publication Number Publication Date
CN116635027A true CN116635027A (zh) 2023-08-22

Family

ID=81754916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180079063.9A Pending CN116635027A (zh) 2020-11-25 2021-11-24 C-利钠肽的延长释放水凝胶偶联物

Country Status (5)

Country Link
US (1) US20240041982A1 (https=)
EP (1) EP4251150A4 (https=)
JP (2) JP7837333B2 (https=)
CN (1) CN116635027A (https=)
WO (1) WO2022115563A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236278A1 (en) 2021-12-13 2023-06-22 Kennett Sprogoe Effective doses of cnp conjugates
IL316466A (en) 2022-05-23 2024-12-01 Ascendis Pharma Growth Disorders As Liquid pharmaceutical formulations of cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103945870A (zh) * 2011-09-07 2014-07-23 普罗林科斯有限责任公司 生物可降解交联的水凝胶
CN108697766A (zh) * 2015-12-08 2018-10-23 生物马林药物股份有限公司 C型钠尿肽变体在治疗骨关节炎中的用途
CN109414469A (zh) * 2016-03-16 2019-03-01 普罗林科斯有限责任公司 艾塞那肽类似物的缓释偶联物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1105409E (pt) * 1999-05-17 2006-07-31 Conjuchem Inc Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
WO2010033216A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
ES2608457T3 (es) * 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
EP3242689A1 (en) * 2015-01-09 2017-11-15 Ascendis Pharma Growth Disorders A/S Cnp prodrugs
IL259827B2 (en) * 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
LT3400019T (lt) * 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
NZ743487A (en) * 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
US11896671B2 (en) * 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
WO2020206358A1 (en) * 2019-04-05 2020-10-08 Prolynx Llc Improved conjugation linkers
KR20220004134A (ko) * 2019-04-26 2022-01-11 프로린크스 엘엘시 서방형 사이토카인 컨쥬게이트

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103945870A (zh) * 2011-09-07 2014-07-23 普罗林科斯有限责任公司 生物可降解交联的水凝胶
CN108697766A (zh) * 2015-12-08 2018-10-23 生物马林药物股份有限公司 C型钠尿肽变体在治疗骨关节炎中的用途
CN109414469A (zh) * 2016-03-16 2019-03-01 普罗林科斯有限责任公司 艾塞那肽类似物的缓释偶联物

Also Published As

Publication number Publication date
EP4251150A4 (en) 2025-04-23
WO2022115563A1 (en) 2022-06-02
JP2023550784A (ja) 2023-12-05
JP2025176137A (ja) 2025-12-03
EP4251150A1 (en) 2023-10-04
JP7837333B2 (ja) 2026-03-30
US20240041982A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
CN116635027A (zh) C-利钠肽的延长释放水凝胶偶联物
US20260007768A1 (en) Conjugation linkers
JP7350123B2 (ja) 大型のキャリアー部分を有するｃｎｐプロドラッグ
CN102625695B (zh) 长效胰岛素组合物
JP4113778B2 (ja) 真性糖尿病の治療方法
ES2390270T3 (es) Compuestos de GLP-1 unidos a polietilenglicol
JP2024016208A (ja) Ｃｎｐプロドラッグ
US9522945B2 (en) Long-acting oxyntomodulin variants and methods of producing same
AU2012261869B2 (en) Long-acting GLP-1/Glucagon receptor agonists
CN108472380B (zh) 具有增加的nep稳定性的控制释放cnp激动剂
KR102627405B1 (ko) 조절 방출 pth 화합물을 위한 투여 용법
US20210214412A1 (en) Glucose-responsive insulin
IL269991B2 (en) Delayed release transfer systems featuring non-trace links
EP3922269A1 (en) Extended release conjugates of exenatide analogs
CN109789221A (zh) 控释pth化合物中的递增剂量发现
EP4442700A1 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
CN112043835A (zh) 用于含氮和羟基的药物的生物可逆引入基团
JP4064453B2 (ja) 成長ホルモンおよびバリンを含んでなる医薬製剤
SK1702004A3 (sk) Farmaceutický prostriedok na liečenie diabetu, jeho použitie a súprava obsahujúca tento prostriedok
WO2019211842A1 (en) Long-acting human growth hormone-antagonists and methods of producing the same
US20190160152A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
KR20080041661A (ko) 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬
WO2023001186A1 (zh) 多肽缀合物在制备治疗糖代谢相关疾病的药物中的应用
HK40069215A (en) Controlled-release cnp agonists with increased nep stability
HK1259384B (zh) 具有增加的nep稳定性的控制释放cnp激动剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination